TD Cowen Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price boosted by TD Cowen from $35.00 to $37.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. cut their price target on ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Monday, November 17th. Weiss Ratings reissued a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. UBS Group upped their price target on shares of ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Piper Sandler set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $30.74.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ ACAD opened at $24.64 on Thursday. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $28.35. The stock has a market cap of $4.17 billion, a P/E ratio of 10.76, a price-to-earnings-growth ratio of 8.73 and a beta of 0.66. The firm has a 50-day moving average of $25.58 and a 200 day moving average of $24.45.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 13.96%. The business had revenue of $298.00 million for the quarter, compared to analysts’ expectations of $292.54 million. During the same quarter in the prior year, the company earned $0.86 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Research analysts expect that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Jennifer J. Rhodes sold 6,950 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the sale, the executive vice president directly owned 7,609 shares in the company, valued at approximately $177,898.42. The trade was a 47.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 26.50% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

Several large investors have recently modified their holdings of ACAD. Farther Finance Advisors LLC lifted its holdings in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 386 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at about $26,000. Geneos Wealth Management Inc. lifted its stake in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 756 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 885 shares during the period. Finally, Transamerica Financial Advisors LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 304.5% in the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 1,005 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 results materially beat EPS expectations: ACAD reported $1.60 EPS (vs. $0.12 consensus) and $298M revenue, with revenue up ~9% YoY — a clear near-term fundamental positive that supports valuation re-rating. Earnings / Transcript
• Positive Sentiment: Management set 2026 revenue targets of roughly $1.2–$1.28B and highlighted commercial momentum for DAYBUE and NUPLAZID, giving investors a revenue-growth roadmap for next year. Seeking Alpha: 2026 targets
• Positive Sentiment: Multiple analyst actions lifted sentiment — TD Cowen raised its target to $37 (buy), Citizens JMP to $35 (market outperform), and Wolfe Research initiated coverage with an outperform and $33 target — signaling several firms see substantial upside from current levels. Analyst Notes
• Neutral Sentiment: Full earnings materials and call transcript/slide deck are available for detailed review (management commentary covers commercial performance and pipeline updates); useful for investors who want to dig into assumptions behind guidance. Earnings Call Transcript
• Neutral Sentiment: Short-interest reports appearing in data feeds show anomalous zero/NaN values for February; this looks like a reporting glitch and is not a reliable signal of rising short pressure.
• Negative Sentiment: Analysts and headlines flagged an EU setback for trofinetide and a mixed sales read — Zacks notes a sales miss and regulatory/cloud on trofinetide’s EU outlook, which could temper upside for pipeline-derived revenue. Zacks: EU setback
• Negative Sentiment: Some analyst trims introduced headwinds — RBC trimmed its target to $30 and Stifel cut to $24 (hold), creating mixed street sentiment even as other firms raised targets. Analyst Moves
• Negative Sentiment: Broader policy risk for midsize biotechs (debate over MFN / pricing proposals) remains an overhang for the sector and can pressure valuations if regulatory action gains traction. FierceBiotech: Policy risk

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.